Juan Pablo Navarro-Garcia De Llano

Dr. Juan Pablo Navarro-Garcia De Llano

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2024 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
BFBeatriz I Fernandez-Gil
Beatriz I Fernandez-Gil
PSPaula Schiapparelli
Paula Schiapparelli
JLJuan Pablo Navarro-Garcia De Llano
Juan Pablo Navarro-Garcia De Llano
AOAndrea Otamendi-Lopez
Andrea Otamendi-Lopez
MUMaria Jose Ulloa-Navas
Maria Jose Ulloa-Navas
AQAlfredo Quinones-Hinojosa
Alfredo Quinones-Hinojosa

30 October 2025 in Cancers
Verified
Journal Article
Open access
PDF file
JLJuan Pablo Navarro-Garcia De Llano
Juan Pablo Navarro-Garcia De Llano
HIHarshvardhan Iyer
Harshvardhan Iyer
HHHarry Hoffman
Harry Hoffman
MSMahesh Seetharam
Mahesh Seetharam
SASteven Attia
Steven Attia
OAOluwaseun O. Akinduro
Oluwaseun O. Akinduro
Background/Objectives: Chordoma, a rare slow-growing malignant bone tumor, remains therapeutically challenging due to its invasive nature. We examined institutional outcomes comparing imatinib and brachyury-directed vaccines. Methods: We used data from three sites of our quaternary care academic institution to analyze demographics, time to progression, overall survival, and adverse events in chordoma patients treated with imatinib or enrolled in a brachyury vaccine trial. Results: We included a total of 52 patients (8 in the brachyury vaccine cohort and 44 in the imatinib cohort) in the analysis. As expected, sacrococcygeal location was the most predominant in both cohorts: 62.5% in the brachyury cohort and 45.5% in the imatinib cohort. No demographic differences were present between the cohorts. ECOG was similar in both groups (p = 0.796). The primary outcome, time to progression (TTP), was shorter in the brachyury compared to the imatinib cohort (5.6 vs. 13 months, p = 0.0589), almost reaching statistical significance. Overall survival (OS) was comparable, 211 vs. 212 months for the brachyury and imatinib cohorts, respectively (p = 0.277). Although the brachyury vaccine cohort presented a higher incidence of adverse events than the imatinib cohort (75% vs. 31.8%, p = 0.021), the severity was milder. Conclusions: Imatinib showed longer disease control than the brachyury vaccine, though overall survival was similar. Future studies and deeper molecular insights are essential to develop better therapies and improve patient quality of life.

18 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HIHarshvardhan Iyer
Harshvardhan Iyer
JSJesus E. Sanchez-Garavito
Jesus E. Sanchez-Garavito
JZJorge Rios Zermeno
Jorge Rios Zermeno
ARAndrew Roberts
Andrew Roberts
JLJuan Pablo Navarro-Garcia De Llano
Juan Pablo Navarro-Garcia De Llano
KAKingsley O. Abode-Iyamah
Kingsley O. Abode-Iyamah
Background/Objectives: Postoperative opioid exposure after lumbar fusion remains a key clinical concern. Understanding which perioperative factors are associated with lower postoperative opioid use may help optimize recovery after minimally invasive (MIS) transforaminal lumbar interbody fusion (TLIF). This study aimed to determine if patients undergoing MIS-TLIF under spinal anesthesia (SA) showed lower postoperative opioid use compared to those undergoing MIS-TLIF under general anesthesia (GA). Methods: We retrospectively studied all adult patients (>18 years) undergoing 1- and contiguous 2-level MIS-TLIFs performed by a single surgeon. Patients undergoing the procedure under GA were compared to those undergoing the procedure under SA. Postoperative oral opioid use, up to 3 months post discharge, was collected. A 1:1 propensity score matching (PSM) protocol was implemented. Each outcome variable was initially assessed using univariate regression. Predictor variables with a p-value < 0.2 were included in the multivariate regression model. This was a retrospective, non-randomized study, and residual confounding cannot be excluded despite PSM. Results: The matched groups (n = 50 in each group) did not differ significantly depending on demographics or levels fused. Before regression, mean number of postoperative opioid prescriptions (p = 0.03), mean total operating room (OR) time in minutes (p < 0.01), and median length of stay (LOS) in days (p = 0.03) were significantly different. Multivariate regression showed that the GA group received 216.5 more total morphine milligram equivalents than the SA group (95% CI = 0.7–432.2, p = 0.049). The days of opioid use were higher in the GA group by 3.8 days (95% CI = 0.5 to 7.1, p = 0.025). On multivariate regression, LOS in hours was greater in the GA group by 14.1 h (p = 0.042). Conclusions: SA is an effective anesthetic modality for spinal surgery with the advantages of reduced postoperative opioid use, reduced OR time, and shorter LOS compared to GA.

3 April 2026 in Applied Sciences
Verified
Journal Article
Open access
PDF file
HIHarshvardhan Iyer
Harshvardhan Iyer
JLJuan Pablo Navarro-Garcia De Llano
Juan Pablo Navarro-Garcia De Llano
EWElaina Wang
Elaina Wang
WJWalter R. Johnson
Walter R. Johnson
RSRahul A. Sastry
Rahul A. Sastry
OAOluwaseun O. Akinduro
Oluwaseun O. Akinduro
Management of unstable upper lumbar fractures with corpectomy and posterior fixation is technically demanding, and conventional workflows may require intraoperative repositioning, increasing operative complexity. Lateral mini-open upper lumbar corpectomy (LMULC) paired with robotic-assisted (RA) posterior percutaneous pedicle screw fixation (PPPSF) can be performed in a single position to facilitate ventral spinal decompression and stabilization in the anatomically constrained upper lumbar spine. In this study, we describe the operative technique and report four illustrative cases of unstable L1 or L2 fractures treated with single-position LMULC, RA-PPPSF, and short-segment fusion. Clinical, radiological, intraoperative variables and postoperative outcomes were evaluated. The mean age was 52.3 ± 17.7 years. The median operation time was 314 min (range 268–361 min); the median estimated blood loss (EBL) was 225 mL (range 100–400 mL). The median preoperative kyphosis was 10.15° (range 8.4–14.6°), the median postoperative kyphosis measured 6.65° (range 1.7–10.8°) and the median correction achieved was 3.5° (range −2.4–12.9°). The median visual analog scale (VAS) pain score reduced from 7 (range 7–9) preoperatively to 4.5 (range 2–6) postoperatively at discharge. At a median follow-up of 12 months (range 6–15 months), all patients had uncomplicated recoveries, demonstrated solid fusion on imaging, and reported favorable MacNab outcomes. Single-position LMULC with RA-PPPSF was technically feasible in this preliminary illustrative series and resulted in favorable clinical and radiographic outcomes. However, further studies in larger cohorts are warranted to help confirm these findings and better define the potential advantages and limitations of this technique.